by Truveta staff | Sep 16, 2025 | Research
Continuous glucose monitoring (CGM) is increasingly recognized not only for its role in diabetes management but also for its potential impact on broader health outcomes. A recent consensus statement highlighted the need for additional evidence on CGM use in people...
by Truveta staff | Sep 15, 2025 | Research
Gestational diabetes is one of the most common complications of pregnancy, affecting roughly 5–9% of pregnancies in the United States. When diagnosed and managed early, patients can avoid complications such as high birth weight, preterm delivery, or cesarean section....
by Truveta Research | Sep 5, 2025 | Research, Research Insights
In July 2025, following the CVS formulary change, 9.6% of patients on AOM tirzepatide switched to a different drug. This was more than a 16-fold increase compared with the average earlier in the year. Among AOM tirzepatide users who switched to a different GLP-1...
by Truveta Research | Sep 5, 2025 | Research, Research Insights
AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025 after the CVS GLP-1 formulary change. In contrast, AOM semaglutide increased by +0.1 points...
by Truveta staff | Sep 3, 2025 | Research
What happens to cardiovascular health when patients stop taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications? That’s the focus of new research from investigators at Baylor Scott & White Research Institute and Stony Brook University Hospital,...
by Truveta staff | Aug 28, 2025 | Research
Biomarker testing has transformed cancer care over the past decade, opening the door to targeted therapies that can improve outcomes for patients with advanced disease. Yet despite strong guideline recommendations, many patients with metastatic non-small cell lung...
